Strota/ Newsroom/ 2026-07-14

JBCHEPHARM (J.B. Chemicals & Pharmaceuticals Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-14 · 13 Jul 18:25 · JBCHEPHARM stock page →

Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited… Historically, acquisition / m&a events have moved JBCHEPHARM-type stocks in the bullish direction 48.9% of the next sessions (n=141).

J.B. Chemicals & Pharmaceuticals will suspend trading from the closing hours of July 16, 2026, ahead of its amalgamation with Torrent Pharmaceuticals, according to an NSE filing dated July 13. The exchange has fixed July 17, 2026 as the record date for the merger, which follows NCLT approval received earlier this month. The stock closed at ₹2,460 on July 13, up 1.01% from the previous session and trading just 0.57% below its 52-week high of ₹2,474.

Events like this have historically shown a 48.9% win rate across 141 comparable M&A suspensions in Strota's database, with a net edge of 0.213 percentage points — meaning slightly more than half of such cases saw positive post-event returns, though the average magnitude was modest. The base rate does not predict this specific outcome; it describes how similar corporate actions have performed in aggregate.

The stock has returned 8.96% over one month and 24.17% over three months, with relative volume at 1.4x indicating elevated interest. It trades above both its 50-day and 200-day moving averages, though the 14-day RSI of 80.8 suggests technically overbought conditions. At 55.19x trailing earnings and 9.5x book value, the ₹39,497 crore market-capitalisation company commands a premium to the sector, with return on equity at 18.7%.

What the data establishes: a confirmed suspension timeline and record date, strong recent price momentum, and stretched momentum indicators. What it does not establish: the exchange ratio for the amalgamation, the post-suspension trading timeline, or whether current valuations already reflect merger terms.

The catalyst

Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited shall be suspended w.e.f. July 17, 2026 (i.e., closing hours of trading on July 16, 2026) on account of the Scheme of Amalgamation. · NSE

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

JBCHEPHARM right now

trading +1.01% on the day; P/E 55.19; RSI 80.8. Full JBCHEPHARM analysis →

Sources

J B Chemicals & Pharmaceuticals Ltd up for fifth session — Business Standard
JB Chemicals gets NCLT nod for merger with Torrent Pharma; everything investors need to know — Upstox
NCLT clears Torrent Pharma's merger with JB Chemicals — CNBC TV18
J B Chemicals & Pharmaceuticals Ltd gains for third consecutive session — Business Standard

Keep digging

JBCHEPHARM — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.